Member Info for LordSnooty

Very attractive price.

was an easy target for market makers - an Interims announcing future placings which put the willies up a few small holders, MMs dropped the bid on very slim volume successively to tighten the screws. However, by my reckoning they only garnered about 150k shares nett, less than £10k worth. It'll be interesting to see what today brings.

A £25m company can lose £2.5m in value on £10,000 worth of shares traded by people unwilling to hold a few weeks..

has key investors in its corner By John Harrington September 30 2013, 8:42am Xenetic Biosciences (LON:XEN) is to tap the market for funds as it steps up the pace of its transformation to a US-listed drugs developer. Though the company has cash reserves of around £4.4mln, the monthly burn rate has risen to around £450,000 from the company’s historical level of £250,000, and the burn rate is expected to increase further, as a result of the initiation of the Australian clinical trials, the build-out of the US executive management team and Lexington facility, and the underlying professional costs being incurred in driving the US listing process forward. The company's leading shareholders have given their commitment to support a fund raising exercise, which is likely to take place in the final quarter of this year. Ensuring the availability of capital that will permit the acceleration to and market launch of the group's lead product candidates in the US and Europe, Xenetic said. Meanwhile, the company remains on the look-out for new product candidates that have near-term commercialisation potential. Getting some money-earners on board will get the top line moving, though it is worth noting that the first half of 2013, turnover of £657,000 was almost four times the sales achieved in the whole of 2012. Pre-tax losses in the half-year narrowed to £1.36mln from £1.86mln the year before. http://www.proactiveinvestors.co.uk/companies/news/61616/xenetic-biosciences-has-key-investors-in-its-corner-61616.html

Clearly the plan is to raise funds in the US once listing is achieved there and the share price has found its US level. One or two small sellers so far today - very short-sighted in my view: I expect US listing to spark considerable interest over there which, together with OncoHist and other news, will lead to a substantial re-rating.

out: http://www.investegate.co.uk/xenetic-biosciences/xen/half-yearly-report/201309300700291848P/?fe=1&utm_source=FE%20Investegate%20Alerts&utm_medium=Email&utm_content=Announcement%20Alert%20Mail&utm_campaign=Xenetic%20Biosciences%20Alert

this is the kind of thing which our move will enable us to leave behind once and for all: another example of Leeson's quackery.

One is privy to no more information than the common plebeian. However, the Snooty Gout has begun playing up again recently. Contrary to popular wisdom, which attributes the condition to excessive libation of Port wine, the affliction in the male Snooty line is, rather, a sure portent of epochal and imminent news. I have previously encouraged my many neophytes here and elsewhere to roust out their old coins, raid the children's piggy banks and check the attic for Old Masters in order to buy some more of these soon-to-be-priceless shares. What more can one modest peer do than to add "watch this space"?

(and there are many), know that scrupulous fairness is a family trait that finds its most sublime expression in the patriarch of the Snooty family - in other words, one. It is therefore with no trepidation whatsoever that one gives ones most earnest enjoinder, nay plea, thus far, to all you little investors. Make haste, the sands of time wait for no-one, the hourglass is about to be turned. Shake out those dusty pockets, exchange those Spanish pesetas, those Greek drachmas, those zlottys for some hard currency. What will it matter if you can only afford a few thousand of these priceless share-ingots? Soon even the dreams of Croesus are about to become reality. Listen to Snooty and tremble!

forbid that one should make the obvious retort.

Molecules Maguire checked his EPO-encrusted Rolex Xenograph. Four fifteen - just time enough to catch the shuttle to Boston, Mass. He hurried out onto the Haymarket pavement, shrugging on his Burberry Shamus Special raincoat and hailing a taxi. "Airport, and make it snappy", he drawled to the driver. "Which one, Guv?", came the reply. The CEO checked himself - his instinct was to make a sarcastic reply, but today he had other things on his mind, so instead he simply barked "Heathrow". Later, as he reclined his Lipolaxomax seat in first class, he sipped from his flute and reflected; everything was in place, the deal was almost sealed, but had he omitted anything? Something was nagging him from an inaccessible corner of his mind, somewhere that he couldn't quite draw to the forefront of his consciousness.... To be continued....

another joke from "Chuckles" Leeson. At least this one was nothing to do with golf.

I gather Mr Maguire has spent considerable time in the US recently, in part talking to dozens of investors small and large. I can't say whether the particular fund you point up has been on his list, but I think you are right, these are the kind of people that could be interested in an emerging biopharma junior like XEN. Once XEN listing in the US has taken place, the issue of liquidity will need to be addressed. Of course upward movement of the share price will naturally release some long-held shares into the market, but probably not enough to interest big funds such as the one to which you provide a link. Much of the XEN share issue is tied up in Russia, India and by Baxter, as well as by board members. The obvious solution is first to list in the US and let the stock find its level on NASDAQ, a vastly different and better-understood market for junior pharmas than AIM, next, get some hard trial data published - first probably OncoHist, later PSA-EPO - then when the time is right tap the market for the funds necessary to put some of XEN's dormant drug candidates into clinical trials.

with Scott Maguire, CEO of Xenetic. First go here: http://urbusinessnetwork.com/scott-maguire-of-xenetic-biosciences-on-myob/ Then click on "Listen to the podcast" at the bottom of the article. Pop-up appears. Click on the same words on the pop-up to listen to podcast. Exciting times!

??

CP22 - looking at Leeson's jokes one can understand why you went elsewhere; they are enough to put one off one's kippers and kedgeree of a morning. However, a glance at the potential and timeline of upcoming events at XEN might be enough to change your mind. Soon we will sail in the Doldrums no longer! Snooty can sniff the salt breeze quickening from the East, shortly to carry us to the New World where, it is said, the Biopharma Index has performed 40% better than the NASDAQ average so far this year. "Blow, till thou burst thy wind, if room enough!"

My best guess, without looking closely, is that there is still several millions in the kitty - funding is not an immediate problem. As regards dilution, yes, Scott said that there will be very minor dilution - what he called 'the cost of listing' - again I don't regard that as significant. Our problems have not been negative results, they have been no results, due to delays in both India and Russia. I have heard nothing but positive news on our two leading candidates - PSA-EPO in India and OncoHist in Russia - so far. I think the current share price, which has not improved in many months - reflects both the delays we have experienced and the risk-aversion of AIM to the biopharma sector. Since I am expecting news on US listing in the next weeks and months, my own opinion is that it is a good time to top up. However, all the usual DYOR etc caveats should apply.

Followers of Snooty! This Leeson wants your shares and he aims to BORE them out of you with his increasingly tedious jokes. Turn your heads I say, and double your resolution! The time is very nearly at hand when Changi Chuckles, such as they are, will be drowned in the ocean of dollars that are shortly coming our way.

Tux helpfully points out the sequence of events regarding Baxter. The $1m licence extension fee was paid as due in June/July, some compensation for the all-to-familiar tale of delays in the pharma industry. Our primary focus in the short term should I believe be, in no particular order, US listing, Big Pharma deal, OncoHist results from Russia. Certainly Lady Snooty has already been eyeing the newest range of diamante-encrusted corsets at the haberdashers in UnterSnooty, our local village here in Prussia. One suspects she has not only a taste for flamboyance familiar in Ladies of Girth, but also that unerring female nose for windfalls about to rain from heaven on their menfolk. One at least has hopes of a decent case of Calvados and a few Cohibas before good fortune is snatched away.....

I don't know the details but I gather that the first trial was messed up by SIIL or their contractors in India. Then there was a three-month moratorium on ALL drug trials in India (now lifted). So basically they have just now started again. Frustrating, but a couple of points to remember - firstly, it is, as the February announcement said, a candidate jointly-owned with SIIL, so there was not a lot XEN could do about it but swallow their frustration. And secondly that the results of this will combine with other results of PSA-EPO in Russia and in OZ, and when that trial data is at a sufficiently advanced stage, XEN will seek to licence it out. More immediately, US listing news and OncoHist results, we hope.